• About Us
  • Strategy
  • Our Team
  • Portfolio
  • News
  • Contact
  • Featured News

    CartiHeal has been acquired by Smith & Nephew for up to $330 million

    Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that it has entered into a definitive agreement to acquire CartiHeal, developer of Agili-C, a novel sports medicine technology for cartilage regeneration in the knee. Under the terms of the agreement, Smith+Nephew will pay an initial cash consideration of $180 million at closing, and up to a further $150 million contingent on financial performance.

    Read More

    May 22, 2024

    Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.

    Better Therapeutics assets include the first FDA-authorized prescription digital therapeutic for type 2 diabetes, AspyreRx, as well as development candidates BT-002, BT-003 and BT-004 for hypertension, hyperlipidemia, and MASH.
    Initial efforts will focus on further development of AspyreRx to adapt it for the treatment of obesity and to benefit from Click’s AI-enabled platform as part of Click’s obesity digital therapeutic in development, CT-181; Click does not plan to self-commercialize AspyreRx as-is at this time.
    CT-181 will be optimized for combination use with anti-obesity and diabetes medications such as GLP-1s, including current injectables and future oral formulations, with the goal of improving treatment persistence, outcomes, and value.

    Apr 01, 2024

    Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn™, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms

    In a landmark clinical study, this innovative adjunctive treatment delivered via smartphone app reduced depression symptoms in participants on antidepressant medication with no treatment-related adverse events

    Jan 08, 2024

    NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates

    Preliminary unaudited revenue expected to be between $17.5 million and $18.0 million for Q4 2023 and between $64.9 million and $65.4 million for full year 2023, beginning 2024 with cash balance of $66.5 million.

    Announced completion of patient implant milestone in the NAUTILUS trial.

    Completed initial milestones in first strategic data collaboration, using proprietary biomarker monitoring and data analysis capabilities to support a clinical-stage biotechnology company’s clinical trial.

    Pilot Launch of Project CARE program to advance RNS System access to community setting expected in 1H 2024.

    Dec 21, 2023

    NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study

    NAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy. Neuromodulation therapy is not currently indicated for patients with drug refractory generalized epilepsy. If successful, NeuroPace’s RNS System would represent the first neuromodulation indication in idiopathic generalized epilepsy

    Dec 05, 2023

    NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration

    First of its kind, multi-year collaboration leverages RNS System’s data to track responses of implanted RNS System patients enrolled in a biotechnology company’s clinical trial. In strategic data collaboration, clinical-stage biotechnology company to pay NeuroPace up to $3.7 million over two years to gain non-exclusive access to NeuroPace’s proprietary biomarker monitoring and data analysis capabilities for trial patients

    Nov 28, 2023

    Keystone Dental Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

    Q3 revenue increased 18.9% year-over-year to $16.8M, including $11.9M from the U.S.

    Check-Cap shareholders to vote on proposed Business Combination Agreement with Keystone Dental at Annual General Meeting on Monday, December 18th, 2023

    Nov 24, 2023

    CartiHeal has been acquired by Smith & Nephew for up to $330 million

    CartiHeal, founded in 2009 by Altschuler in collaboration with Ben-Gurion University, raised $74 million from venture capital funds aMoon, Elron, Peregrine Ventures, Access Medical Ventures, Pertec, Accelmed, and JJDC - the venture capital fund of J&J.

    Nov 13, 2023

    Keystone Dental Announces Launch of the GENESIS ACTIVE™ Dental Implant System: Revolutionizing Dental Implantology

    Keystone Dental Holdings (“Keystone Dental” or the “Company”), a pioneer in dental implant technology, announced today the commercial launch of GENESIS ACTIVE Implant System, a state-of-the-art surgical solution that is expected to transform how dental professionals approach implant placement and restoration.

    Nov 06, 2023

    Keystone Dental Announces Market Launch of Nexus Connect, the First A.I. Enabled Intraoral Implant-Scan Analyzer for the Nexus iOS Full-Arch Solution

    Nexus Connect is a free software that provides real-time chairside results designed to compare intraoral scan gauge scans and give users direct feedback regarding the accuracy of their implant scans

    Oct 18, 2023

    NeuroPace Announces RNS System Enhancements Designed to Streamline Care

    NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced a series of key enhancements to its RNS System, all designed to streamline care. The nSight Platform, Simple Set Programming, and the Tablet Remote Monitor are all designed to simplify the experience with the RNS System for both clinicians and patients, and to improve patient care.

    Aug 17, 2023

    Keystone Dental Holdings and Check-Cap Ltd Enter into Definitive Business Combination Agreement

    Proposed business combination to create a Nasdaq-listed medical device company focused on advancing the commercial execution and market development of Keystone’s comprehensive portfolio of implants, arches and other tooth replacement solutions. Keystone 2022 revenues exceeded $60 million. The combined company will trade on the NASDAQ with the ticker “KSD"Keystone 2022 revenues exceeded $60 million. The combined company will trade on the NASDAQ with the ticker “KSD"

    Dec 28, 2022

    Minerva Surgical Announces $30 Million Private Placement of Common Stock Led by Accelmed Partners

    Minerva Surgical, Inc. a women’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it has entered into a share purchase agreement for the sale of 146,627,565 shares (subject to adjustment for any stock split occurring prior to closing) of its common stock in a private placement, led by Accelmed, with participation by New Enterprise Associates, at an offering price of $0.2046 per share (subject to adjustment for any stock split occurring prior to closing). Following the offering, Accelmed will become the controlling stockholder of Minerva Surgical.

    Dec 20, 2022

    Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for Schizophrenia

    Boehringer Ingelheim and Click Therapeutics today announced the launch of an expanded collaboration for the development and commercialization of a second prescription-based digital therapeutic (PDT). The companies will collaborate to develop and commercialize a novel mobile application, which combines multiple clinically validated therapeutic interventions for use alone and in combination with pharmaceutical therapy to help people with schizophrenia achieve positive clinical outcomes.

    Dec 16, 2022

    Click Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic to Treat Episodic Migraine

    Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for CT-132. Click’s CT-132 prescription digital therapeutic is under development as an adjunctive preventive treatment for episodic migraine in patients aged 18 years and older.

    Dec 16, 2022

    Veranex Acquires Fusion Biotec to Continue Accelerating MedTech Diagnostic Solutions

    Veranex, the only truly comprehensive, global, tech-enabled service provider dedicated to the MedTech industry, announced today that it has acquired Fusion Biotec (Fusion), a design and engineering leader for complex electro-mechanical diagnostic instrumentation and medical devices located in Orange, California.

    Dec 08, 2022

    EndoGastric Solutions, Inc.® Announces CEO Transition and $18M Financing to Expand Commercialization

    Darin Hammers appointed Chief Executive Officer
    EGS closes on $18M financing to further drive growth and adoption of the Transoral Incisionless Fundoplication (TIF) procedure

    Nov 14, 2022


    Helps Customized Rx Dermatology and Digital Health Company Accelerate Expansion of Product Offerings, Platform Technologies, and Operational Footprint to Enhance Practice Care

    Nov 14, 2022

    Accelmed announces its investment in Veranex

    Veranex brings together best-in-class expertise in product design and engineering, medical device evaluation, clinical development, data management, regulatory, and market access to deliver an integrated and comprehensive solution to the MedTech market, enabling its customers to efficiently move from concept to commercialization.

    Sep 20, 2022

    Veranex Expands European MedTech Capabilities With Acquisition of Medidee

    The only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry, announced today that it has acquired Medidee, a top MedTech consultancy company headquartered in Lausanne, Switzerland.

    Aug 31, 2022

    MedMinder Expands Aging at Home Care with $35M Investment

    MedMinder, the leader in connected pharmacy care for polypharmacy and senior patients, announced today it has closed an additional $35 million in funding through a credit facility with SWK Holdings Corporation and additional investment from existing equity partner, Accelmed Partners.

    Aug 08, 2022

    Accelmed Partners II (AP-II) Q2 2022 Update

    While focusing on securing liquidity for our portfolio companies and taking measures to contain costs, we continue to seek new investments and are glad to report a new member of the Accelmed portfolio, Veranex.

    May 19, 2022

    Veranex Announces Strategic Investments From Accelmed Partners and Lauxera Capital Partners

    Veranex — the only global, tech-enabled product development services provider focused on the medical technology industry — today announced strategic partnerships with Accelmed Partners II and Lauxera Capital Partners.

    Oct 22, 2021

    Accelmed and H.I.G. BioHealth Co-Lead $52 Million Series B for Click Therapeutics

    Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that it has closed a $52 million upsized Series B financing

    Sep 01, 2021

    Keystone Dental acquires Osteon Medical, raises $25m led by Nantahala

    Accelmed Partners I portfolio company Keystone Dental Inc. announced the acquisition of Osteon Medical and the completion of a $25 million financing round led by Nantahala, with participation from Accelmed and Migdal Insurance.

    Aug 30, 2021

    CartiHeal to be acquired by Bioventus for $500 million

    Accelmed Ventures portfolio company CartiHeal is being acquired by Bioventus for $350 million in upfront consideration and up to $500 million including earn-outs.

    Aug 13, 2021

    Robotic surgery co Memic agrees $1b valuation SPAC merger

    Memic, a portfolio company of Accelmed, signed a definitive agreement for a SPAC merger with MedTech Acquisition Corporation (Nasdaq: MTAC) with an equity value at over $1 billion.

    Aug 04, 2021

    CartiHeal succeeds in clinical trial for cartilage treatment

    CartiHeal released a study validating the clear clinical benefits of its Agili-C™ implant for the treatment of cartilage lesions in arthritic and non-arthritic joints. Accelmed was the first investor in CartiHeal.

    Jul 12, 2021

    Project MedTech Podcast

    Managing Partner Dr. Uri Geiger spoke with Duane Mancini, M. Sc. for the Project Medtech podcast and discussed his background, Israel’s medical device space and what they look for in a company, among other things.

    Jun 14, 2021

    Five Questions with Accelmed Managing Partner Uri Geiger

    Managing Partner Dr. Uri Geiger sat down for a Q&A with Sarah Pringle of PE Hub to discuss how Accelmed distinguishes itself from traditional private equity funds, its unique differentiators and more.

    Jun 14, 2021

    Accelmed Expands Senior Team With Two New Partners

    Accelmed bolsters its leadership team with the addition of two industry veterans, Eric Tansky and Stephen Rubin as General Partner and Partner respectively, as well as adding Lewis Pell and Stanley Stern to its Executives Network.

    Jun 10, 2021

    Barron’s Webinar - The Healthtech Revolution - A Conversation with AccelMed's Dr. Uri Geiger

    Managing Partner Dr. Uri Geiger sat down with Lauren R. Rublin and Nathan-Kazis for a discussion on developments in pharma and biotech investing, innovations in healthtech, or the intersection of healthcare and technology, private equity investing in the healthcare arena, and healthtech innovations in Israel.

    Mar 22, 2021

    Accelmed Partners Leads $40 Million Investment in MedMinder

    Accelmed Partners Leads a $40 Million Investment in MedMinder, the leading fully-integrated, end-to-end pharmacy, medication adherence and connected care solution for elderly and polypharmacy patients.

    Mar 17, 2021

    Accelmed Partners Raises $400 Million to Invest in Commercial Stage HealthTech

    Accelmed successfully closed its oversubscribed second fund at the Fund’s hard cap of $400 million, exceeding its original $300 million target.

    Mar 16, 2021

    Emerging healthtech investor Accelmed closes Fund II at $400m hard cap

    Accelmed Fund II, unveiled in late 2019, wrapped up this month at its hard cap, 33 percent above an original target of $300 million, founder and managing partner Uri Geiger told Buyouts. Fund II is more than 3x the size of its predecessor, closed in 2016 at $130 million.

    Contact Us

    Partner with Us

    Get in touch